Market Cap | 559.82M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -157.49M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 2.00% |
Sales | 89.54M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 10.00% |
Dividend | N/A | Price/Book | 2.73 | EPS next 5Y | - | 52W High Chg | -13.00% |
Recommedations | - | Quick Ratio | 2.80 | Shares Outstanding | 100M | 52W Low Chg | 73.00% |
Insider Own | 16.19% | ROA | -15.08% | Shares Float | 64.26M | Beta | 1.03 |
Inst Own | 58.08% | ROE | -117.29% | Shares Shorted/Prior | -/- | Price | 5.80 |
Gross Margin | 44.37% | Profit Margin | -175.89% | Avg. Volume | 1,829 | Target Price | - |
Oper. Margin | -74.78% | Earnings Date | Apr 29 | Volume | 58 | Change | 0.00% |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.